The effect of an anti-lgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

摘要

A humanized murine monoclonal antibody directed to the FcεR1-binding domain of human lgE (rhuMAb- E25) has been shown to inhibit the binding of lgE to mast cells without provoking mast cell activation. To examine the effects of neutralizing lgE on allergic airway responses, we assessed the effects of 9 wk Of treatment with rhuMAb-E25 in a parallel group, randomized, double-blind, placebo-controlled study Of 19 allergic asthmatic subjects.